TRAVERE THERAPEUTICS, INC.

SAN DIEGO, CA How do I update this listing?

Travere Therapeutics is based out of San Diego. Retrophin, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orphan drugs for the treatment of rare and life-threatening diseases. The company develops treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. Its products include RE-021, a small molecule angiotensin receptor blocker and selective endothelin receptor antagonist for the treatment of FSGS; and RE-024, a drug that restores the disruption in the biochemical Coenzyme A pathway caused by the non-functioning PANK2 encoded enzyme.Whalewisdom has at least 123 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2013-10-07. The notice included securities offered of Equity,Option, Warrant or Other Right to Acquire Another Security

Create Alert

Contact Info

travere therapeutics, inc.
3611 VALLEY CENTRE DR
SAN DIEGO CA    92130

Business Phone: 888-969-7879
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2013-10-07 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security 24,916,307 24,916,307 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
HORACIO PLOTKIN subscription required
    EXECUTIVE OFFICER
MARC PANOFF subscription required
    EXECUTIVE OFFICER
MARTIN SHKRELI subscription required
    EXECUTIVE OFFICER DIRECTOR
STEPHEN ASELAGE subscription required
    DIRECTOR
STEVE RICHARDSON subscription required
    DIRECTOR

Elevate your investments